195 related articles for article (PubMed ID: 20022310)
1. Clinical experience with exenatide in a routine secondary care diabetes clinic.
Natarajan B; Edavalath M; Davies J; Jenkins L; Marshall-Richards N; Evans D; Price DE; Bain SC; Stephens JW
Prim Care Diabetes; 2010 Apr; 4(1):57-60. PubMed ID: 20022310
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
3. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
4. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
5. Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267.
Home PD
Diabetologia; 2007 Jul; 50(7):1561-2; author reply 1563-4. PubMed ID: 17384924
[No Abstract] [Full Text] [Related]
6. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
[TBL] [Abstract][Full Text] [Related]
7. [Therapy with incretin mimetic exenatide. Soon HbA1c value and weight decrease permanently].
MMW Fortschr Med; 2006 Sep; 148(37):55. PubMed ID: 17036908
[No Abstract] [Full Text] [Related]
8. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O
Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
10. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
12. [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
Perusicová J; Haladová I; Pit'hová P; Acsová D; Belobrádková J; Belzová A; Berková K; Dolezalová B; Dvoráková H; Hejnicová K; Hudcová M; Kallmünzerová D; Krejsová Z; Markofová G; Müllerová H; Owen K; Pelikánová M; Raclavská L; Racická E; Skarpová O; Váchová A; Veselá A; Vyoralos J; Broz J; Edelsberger T; Honka M; Hrdina T; Chmura P; Tosovský J
Vnitr Lek; 2013 Mar; 59(3):165-71. PubMed ID: 23713182
[TBL] [Abstract][Full Text] [Related]
13. [Improved blood sugar control plus weight loss].
Göke B
MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
[No Abstract] [Full Text] [Related]
14. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
16. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
[TBL] [Abstract][Full Text] [Related]
17. Effects of exenatide in poorly controlled type 2 diabetes.
Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
[TBL] [Abstract][Full Text] [Related]
18. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
Buysschaert M; Preumont V; Oriot PR; Paris I; Ponchon M; Scarnière D; Selvais P;
Diabetes Metab; 2010 Nov; 36(5):381-8. PubMed ID: 20598606
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
[TBL] [Abstract][Full Text] [Related]
20. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
Riddle MC; Henry RR; Poon TH; Zhang B; Mac SM; Holcombe JH; Kim DD; Maggs DG
Diabetes Metab Res Rev; 2006; 22(6):483-91. PubMed ID: 16634116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]